Related Experiment Video
Updated: Mar 1, 2026
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure
Michael Lichtenauer1, Peter Jirak1, Bernhard Wernly1
1Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria.
Insights
Novel cardiovascular biomarkers, including soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR), and heart-type fatty acid binding protein (H-FABP), show promise for diagnosing heart failure. H-FABP and sST2 were the most effective markers in patients with ischaemic or dilative cardiomyopathy.
Area of Science:
- Cardiology
- Biomarker Discovery
- Heart Failure Research
Background:
- Heart failure (HF) with reduced ejection fraction presents significant therapeutic challenges.
- Investigating novel cardiovascular biomarkers is crucial for improving HF management.
- Existing treatments for HF with reduced ejection fraction require further refinement.
Purpose of the Study:
- To evaluate the diagnostic role of novel biomarkers: sST2, GDF-15, suPAR, and H-FABP.
- To assess these biomarkers in patients with ischaemic cardiomyopathy (ICM) and dilative cardiomyopathy (DCM).
- To compare biomarker levels between HF patients and a healthy control group.
Main Methods:
- A cohort of 200 patients was studied, including 65 with DCM, 59 with ICM, and 76 controls.
- Plasma samples were analyzed using enzyme-linked immunosorbent assay (ELISA).
- Statistical analysis correlated biomarker levels with clinical parameters like ejection fraction, CRP, renal insufficiency, and diabetes.
Main Results:
- sST2, suPAR, and H-FABP levels were significantly elevated in both ICM and DCM patients compared to controls (p<0.0001).
- Ejection fraction showed inverse correlations with all tested biomarkers (p<0.0001 for sST2 and H-FABP).
- Renal insufficiency and diabetes were significantly associated with increased cardiac biomarker levels.
Conclusions:
- Novel biomarkers sST2, GDF-15, suPAR, and H-FABP hold potential for precise diagnosis in ICM and DCM.
- H-FABP emerged as the most promising marker, followed by sST2, uPAR, and GDF-15.
- Further prospective studies are needed to confirm the clinical utility of these biomarkers in routine HF treatment.
Background:
Heart failure (HF) with reduced ejection fraction remains a major therapeutic challenge. The aim of this study was to investigate the role of novel cardiovascular biomarkers, i.e. soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) in patients with ischaemic (ICM) or dilative cardiomyopathy (DCM).
Materials And Methods:
A total of 200 patients were enrolled in this study: 65 were diagnosed with DCM and 59 patients suffering from ICM were included. 76 patients without coronary artery disease or signs of heart failure were included as controls. Plasma samples of all patients were analyzed by use of ELISA.
Results:
Levels of sST2, suPAR and H-FABP were significantly higher in ICM and DCM patients compared to the control group (p<0.0001). However, there were no significant differences between ICM and DCM in biomarker levels. Ejection fraction correlated inversely with cardiac biomarkers (sST2 p<0.0001, GDF-15 p=0.0394, suPAR p=0.0029, H-FABP p<0.0001). Similarly, CRP levels also showed a positive correlation with cardiac biomarkers. Renal insufficiency (p<0.0001) and diabetes (sST2 p=0.0021, GDF-15 p=0.0055, suPAR p=0.0339, H-FABP p=0.0010) were significantly associated with a rise in cardiac biomarkers.
Conclusion:
Novel cardiovascular biomarkers such as ST2, GDF-15, uPAR and H-FABP could offer a great potential for more precise diagnostic in ICM and DCM patients. H-FABP was the most promising marker in our study, followed by sST2, uPAR and GDF-15. Additional prospective studies will be necessary to further evaluate the potential clinical benefits in routine treatment of HF.
More Related Videos
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:30Heart Failure V: Medical Management
01:30Cardiomyopathy II: Dilated Cardiomyopathy